SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Lou Gehrig — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientLou Gehrig
Date of birth1903-06-19
IdentifiersMRN HR-ET018-SYN-TD; SSN (made up) 000-18-6620
Document date1939-06-29
AuthorGavin Hollister, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six weeks after diagnosis: riluzole safety, genetic test result, the ALS clinic plan, mobility, mood, and work. [S]

History of Present Illness

Mr. Gehrig returns six weeks after the diagnosis, a week after his first full visit to the multidisciplinary ALS clinic, where he saw the physical, occupational and speech therapists, the dietitian, the respiratory therapist and the social worker. He has taken riluzole twice daily; he had mild nausea in the first week, which settled. The genetic panel found no disease-causing variant in SOD1, C9orf72, FUS, TARDBP or the other genes tested. His grip is weaker and he has tripped twice without falling; the clinic measured him for a left ankle-foot orthosis. He has decided to stop playing professionally and plans to say so publicly soon, and he is thinking about work he could do at a desk. He has been sleeping poorly and feels low at times but enjoys time with friends. [S]

ElementDetail
RiluzoleTwice daily; nausea in the first week, settled
Genetic testingNo disease-causing variant found
FunctionGrip weaker; two trips without a fall; orthosis measured
WorkDecided to stop playing; considering desk work
MoodLow at times; poor sleep

Review of Systems

SystemResultFinding
NeurologicalPositiveWeaker grip; left foot catching; cramps at night
Ears, nose, mouth, and throatNegativeNo slurred speech or choking
RespiratoryNegativeNo breathlessness or orthopnea
GastrointestinalNegativeNausea gone; appetite good
PsychiatricPositiveLow at times; poor sleep; no thoughts of self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Riluzole 50 mg oral tablet, one tablet by mouth twice daily, an hour before or two hours after mealsOne tablet by mouth every 12 hours on an empty stomachOral route1939-05-18activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1939-06-29Body height183cmS
1939-06-29Body weight88.4kgS
1939-06-29Body mass index (BMI) [Ratio]26.4kg/m2S
1939-06-29Systolic blood pressure120mm[Hg]S
1939-06-29Diastolic blood pressure76mm[Hg]S
1939-06-29Heart rate72/minS
1939-06-29Respiratory rate15/minS
1939-06-29Body temperature36.7CelS
1939-06-29Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1939-06-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma38U/L7-55 U/LNormalS
1939-06-29Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma33U/L10-40 U/LNormalS
1939-06-29Forced vital capacity [Volume] Respiratory system4.31L>=4.1 LNormalS
1939-06-29FVC measured/predicted84%80% of predicted or more is normal; noninvasive ventilation is considered below 50%NormalS
1939-06-29Total score [ALSFRS-R]40{score}S
1939-06-29Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]8{score}S

Physical Exam

Vital signs recorded on 1939-06-29; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 120/76, pulse 72; weight 88.4 kg
NeurologicalHand wasting slightly more marked; grip 4-/5 on both sides; left ankle dorsiflexion 4-/5; fasciculations in the arms and legs; reflexes brisk; tongue normal
GaitLeft foot slap; steady with a hand on the rail

Problems

ProblemClinical statusVerificationCodeProvenance
Progressive weakness and loss of coordination for about a year: fumbling with buttons and a bat, tripping on curbs, a fall on the ice in the winter, muscle cramps and twitching in the arms and thighs; no numbness, pain, double vision, or trouble speaking or swallowing. Examination: wasting of the hand muscles (left more than right), fasciculations in both arms and thighs, weakness of grip and of left ankle dorsiflexion, brisk reflexes with spread and a positive Hoffmann sign, normal sensation. Mixed upper and lower motor neuron signs; evaluation for motor neuron disease and its mimics begun, with neuromuscular neurology consultation bookedresolvedconfirmed M62.81S — Synthetic presenting problem anchored to his documented decline in 1938 and 1939; superseded by the diagnosis.
Amyotrophic lateral sclerosis, limb onset: progressive weakness for about a year with upper and lower motor neuron signs in the cervical and lumbosacral regions, and active and chronic denervation on EMG in the cervical, thoracic and lumbosacral regions with normal sensory nerve conduction; MRI of the brain and cervical spine and blood tests exclude mimics. Meets the Gold Coast criteria and the revised El Escorial category of clinically probable ALS. ALSFRS-R 42 and FVC 88% of predicted at diagnosis. Synthetic modern episode linked to his documented diagnosisactiveconfirmed G12.21S — Synthetic modern diagnosis; the documented 1939 diagnosis is the anchor. EMG findings, scores and timing are synthetic.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyALSFRS-REvery 2 to 3 months in the multidisciplinary ALS clinicCompleted today40 of 48 (42 at diagnosis)
ImagingSeated forced vital capacityEvery 2 to 3 months in the multidisciplinary ALS clinicCompleted today4.31 L, 84% of predicted
ExaminationMaximal inspiratory pressure; supine capacity and overnight oximetry when values fall or symptoms appearEvery 2 to 3 months in the multidisciplinary ALS clinicCompleted todayMaximal inspiratory pressure -80 cmH2O; no orthopnea
ExaminationNoninvasive ventilation criteria (FVC below 50%, maximal inspiratory pressure weaker than -60 cmH2O, nocturnal desaturation, orthopnea)Every 2 to 3 months in the multidisciplinary ALS clinicNot indicatedNo criterion met
ExaminationWeight and BMI (gastrostomy discussion if weight falls 5 to 10% or swallowing is unsafe; place while FVC is above 50%)Every visitCompleted today88.4 kg, 0.9% below diagnosis
ExaminationSpeech and swallowing assessmentEvery 2 to 3 months in the multidisciplinary ALS clinicCompleted todayNormal at the clinic speech assessment; voice banking introduced
SurveyDepression (PHQ-9)Every visitCompleted todayPHQ-9 8, mild
ExaminationSymptoms: cramps, spasticity, saliva, emotional lability, painEvery visitCompleted todayNight cramps, eased by stretching; no spasticity problems, drooling or emotional lability
ExaminationMobility, falls, orthoses and equipmentEvery visitCompleted todayFoot drop; orthosis measured; cane advised
LaboratoryALT on riluzoleMonthly for 3 months, then every 3 monthsDeferredMissed: no liver test was drawn at one month because no visit fell then. ALT 38 U/L today, at six weeks, is normal, so no harm resulted. Corrective action: two- and three-month tests booked with the ALS clinic laboratory
LaboratoryGenetic testing (SOD1 result decides tofersen)Offer at diagnosis to every person with ALSCompleted todayNo disease-causing variant in SOD1, C9orf72, FUS, TARDBP or the other genes tested; tofersen not indicated
ReferralMultidisciplinary ALS clinicEvery 2 to 3 months in the multidisciplinary ALS clinicCompleted todayFirst full clinic visit last week
Self-managementWork, disability benefits and social workFrom diagnosisCompleted todayStopping professional play; exploring desk work and benefits with the social worker
Self-managementAdvance care planningEarly, then at each changeDuePlanned for the preventive visit, at his choice

Goal progress:

Guideline basis: Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review) (2009); Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review) (2009); Evidence-based consensus guidelines for ALS genetic testing and counseling (2023); Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS (2022)

Follow-up: Liver tests at two and three months. ALS clinic in about two months, with primary care the same week. Next scheduled visit 1939-08-24: three months after diagnosis: ALSFRS-R, breathing, weight, speech, mobility equipment, and work accommodations. [S]